Gapping up
In reaction to strong earnings/guidance/SSS:
- QNST +11.9%, (also says Kerrisdale claims in negative report are inaccurate), OZRK +3.3%, MDR +3.3%, ZUMZ +3%, (Zumiez reports March comps of +12.6 %vs +1.1% year ago and +9.2% last month), CBSH +3%, RAD +3%, DAL +2%, BLK +1.5%, BKE +1.1%, CBI +0.5%, COST +0.5%, LB +0.5%
Other news:
- CYRN +23.6% (discloses that it has signed a material contract with one of the world's largest technology companies)
- BLCM +22.6% (FDA has lifted the clinical hold on studies of BPX-501 in the U.S. )
- RETA +11.6% (provides update on the Phase 2 portion of the CARDINAL study of bardoxolone methyl in patients with Alport Syndrome; treatment produced significant increase in kidney function maintained through week 36)
- ALRN +5% (continued strength -- company confirmed after the close the publication of nonclinical results in Science Translational Medicine demonstrating the anti-cancer potential of ALRN-6924 in models of Acute Myeloid Leukemia)
- OSTK +4.3% (stronger with Bitcoin +12%)
- ABUS +2.8% (Arbutus Biopharma and Roivant Sciences entered into an agreement to launch Genevant Sciences; Roivant will contribute $37.5 million in transaction-related seed capital)
- CLDR +2.4% (Director disclosed the purchase of 25k shares)
- FEYE +1.1% (continued strength)
- GSK +1.1% (signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics)
Analyst comments:
- FTI +4.6% (upgraded to Buy from Neutral at Goldman)
- INCY +2.3% (upgraded to Buy from Neutral at UBS)
- MYL +1.1% (upgraded to Outperform from Mkt Perform at Leerink Partners)
![]()